Targeting the osteoblast: Approved and experimental anabolic agents for the treatment of osteoporosis

Hormones

Volumn 10, Issue 3, 2011, Pages 174-195

  Toulis, Konstantinos A ^a   Anastasilakis, Athanasios D ^a   Polyzos, Stergios A ^b   Makras, Polyzois ^c  

^a 424 General Army Hospital   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

Author keywords

Anabolic treatment; Osteoblast; Osteoporosis; Parathyroid hormone; Sclerostin; Teriparatide

Indexed keywords

2 CHLORO 6 [3 [1,1 DIMETHYL 2 (2 NAPHTHYL)ETHYLAMINO] 2 HYDROXYPROPOXY]BENZONITRILE; ACTIVIN; AMG 167; AMG 785; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN; CALCIUM ANTAGONIST; CALCIUM SENSING RECEPTOR; CALHEX 231; DICKKOPF 1 PROTEIN; GROWTH HORMONE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; MONOCLONAL ANTIBODY; OSTABOLIC C; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PEPTIDE[1-36]; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE[1-31][27 LEUCINE] AMIDE 22,26 AMIDE; PARATHYROID HORMONE[1-34]; PLACEBO; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RN 564; RONACALERET; SB 423557; SCLEROSTIN; SEROTONIN; SOMATOMEDIN C; SOTATERCEPT; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN; ZT 031;

ARTHRALGIA; BONE DENSITY; BONE MASS; CARPAL TUNNEL SYNDROME; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIZZINESS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE SEQUENCE; DRUG EFFECT; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FEMUR FRACTURE; FRACTURE HEALING; FRAGILITY FRACTURE; GROWTH HORMONE DEFICIENCY; HIP FRACTURE; HORMONE ACTION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERGLYCEMIA; HYPERTENSION; IMMUNOGENICITY; INFECTION; INTRACELLULAR SIGNALING; LOW DRUG DOSE; MUSCLE CRAMP; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; SWELLING; TARGET CELL; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE;

EID: 80052871452     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1308     Document Type: Review

References (193)

1. Manolagas SC, Parfitt AM, 2010 What old means to bone. Trends Endocrinol Metab 21: 369-374.
2. Manolagas SC, 2010 From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev 31: 266-300.
3. Lyritis GP, Georgoulas T, Zafeiris CP, 2010 Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis. Ann N Y Acad Sci 1205: 277-283.
4. Trivedi R, Goswami R, Chattopadhyay N, 2010 Investigational anabolic therapies for osteoporosis. Expert Opin Investig Drugs 19: 995-1005.
5. Borggrefe J, Graeff C, Nickelsen TN, Marin F, Gluer CC, 2010 Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. J Bone Miner Res 25: 472-481.
6. Hodsman AB, Bauer DC, Dempster DW, et al, 2005 Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26: 688-703.
7. Jilka RL, 2007 Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40: 1434-1446.
8. Corrado A, Neve A, Maruotti N, Gaudio A, Marucci A, Cantatore FP, 2011 Dose-dependent metabolic effect of zoledronate on primary human osteoblastic cell cultures. Clin Exp Rheumatol 28: 873-879.
9. Koch FP, Merkel C, Al-Nawas B, et al, 2010 Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner-A quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2. J Craniomaxillofac Surg Epub ahead of print: PMID: 21030265.
10. Allen MR, Follet H, Khurana M, Sato M, Burr DB, 2006 Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib. Calcif Tissue Int 79: 255-261.
11. Ma YL, Zeng QQ, Porras LL, et al, 2011 Teriparatide [rhPTH (1-34)], But Not Strontium Ranelate, Demonstrated Bone Anabolic Efficacy in Mature, Osteopenic, Ovariectomized Rats. Endocrinology 152: 1767-1778.
12. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC, 1999 Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104: 439-446.
13. Keller H, Kneissel M, 2005 SOST is a target gene for PTH in bone. Bone 37: 148-158.
14. Canalis E, 2010 Update in new anabolic therapies for osteoporosis. J Clin Endocrinol Metab 95: 1496-1504.
15. Martin TJ, Sims NA, Ng KW, 2008 Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis. Osteoporos Int 19: 1125-1138.
16. Trivedi R, Mithal A, Chattopadhyay N, 2010 Anabolics in osteoporosis: the emerging therapeutic tool. Curr Mol Med 10: 14-28.
17. Neer RM, Arnaud CD, Zanchetta JR, et al, 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434-1441.
18. Greenspan SL, Bone HG, Ettinger MP, et al, 2007 Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146: 326-339.
19. Orwoll ES, Scheele WH, Paul S, et al, 2003 The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18: 9-17.
20. Saag KG, Zanchetta JR, Devogelaer JP, et al, 2009 Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60: 3346-3355.
21. Vahle JL, Sato M, Long GG, et al, 2002 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30: 312-321.
22. Jolette J, Wilker CE, Smith SY, et al, 2006 Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol Pathol 34: 929-940.
23. Obermayer-Pietsch BM, Marin F, McCloskey EV, et al, 2008 Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23: 1591-1600.
24. Zanchetta JR, Bogado CE, Cisari C, et al, 2010 Treatment of postmenopausal women with osteoporosis with PTH(1-84) for 36 months: treatment extension study. Curr Med Res Opin 26: 2627-2633.
25. Hodsman AB, Hanley DA, Ettinger MP, et al, 2003 Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88: 5212-5220.
26. Gallacher SJ, Dixon T, 2010 Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review. Calcif Tissue Int 87: 469-484.
27. Foster SA, Foley KA, Meadows ES, et al, 2011 Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance. Osteoporos Int 22: 551-557.
28. Bauer DC, 2011 Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow? J Bone Miner Res 26: 239-241.
29. Lane NE, Silverman SL, 2010 Anabolic therapies. Curr Osteoporos Rep 8: 23-27.
30. Cosman F, Lane NE, Bolognese MA, et al, 2010 Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 95: 151-158.
31. Matsumoto T, Shiraki M, Hagino H, Iinuma H, Nakamura T, 2006 Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study. Osteoporos Int 17: 1532-1538.
32. Nemeth EF, 2008 ZT-031, a cyclized analog of parathyroid hormone(1-31) for the potential treatment of osteoporosis. IDrugs 11: 827-840.
33. Strewler GJ, 2000 The physiology of parathyroid hormone-related protein. N Engl J Med 342: 177-185.
34. Makras P, Papapoulos SE, 2009 Medical treatment of hypercalcaemia. Hormones (Athens) 8: 83-95.
35. Datta NS, Abou-Samra AB, 2009 PTH and PTHrP signaling in osteoblasts. Cell Signal 21: 1245-1254.
36. Karaplis AC, Luz A, Glowacki J, et al, 1994 Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes Dev 8: 277-289.
37. Amizuka N, Karaplis AC, Henderson JE, et al, 1996 Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development. Dev Biol 175: 166-176.
38. Miao D, He B, Jiang Y, et al, 2005 Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest 115: 2402-2411.
39. Kartsogiannis V, Moseley J, McKelvie B, et al, 1997 Temporal expression of PTHrP during endochondral bone formation in mouse and intramembranous bone formation in an in vivo rabbit model. Bone 21: 385-392.
40. Stewart AF, Mangin M, Wu T, et al, 1988 Synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcemia in rats. J Clin Invest 81: 596-600.
41. Henry JG, Mitnick M, Dann PR, Stewart AF, 1997 Parathyroid hormone-related protein-(1-36) is biologically active when administered subcutaneously to humans. J Clin Endocrinol Metab 82: 900-906.
42. Plotkin H, Gundberg C, Mitnick M, Stewart AF, 1998 Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormonerelated peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis. J Clin Endocrinol Metab 83: 2786-2791.
43. Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF, 2003 Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88: 569-575.
44. Horwitz MJ, Tedesco MB, Sereika SM, et al, 2006 Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study. Osteoporos Int 17: 225-230.
45. Horwitz MJ, Tedesco MB, Garcia-Ocana A, et al, 2010 Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J Clin Endocrinol Metab 95: 1279-1287.
46. Brown EM, 2000 Calcium receptor and regulation of parathyroid hormone secretion. Rev Endocr Metab Disord 1: 307-315.
47. Steddon SJ, Cunningham J, 2005 Calcimimetics and calcilytics--fooling the calcium receptor. Lancet 365: 2237-2239.
48. Petrel C, Kessler A, Dauban P, Dodd RH, Rognan D, Ruat M, 2004 Positive and negative allosteric modulators of the Ca2+-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. J Biol Chem 279: 18990-18997.
49. Gowen M, Stroup GB, Dodds RA, et al, 2000 Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 105: 1595-1604.
50. Saidak Z, Brazier M, Kamel S, Mentaverri R, 2009 Agonists and allosteric modulators of the calciumsensing receptor and their therapeutic applications. Mol Pharmacol 76: 1131-1144.
51. Chang W, Tu C, Cheng Z, et al, 2007 Complex formation with the Type B gamma-aminobutyric acid receptor affects the expression and signal transduction of the extracellular calcium-sensing receptor. Studies with HEK-293 cells and neurons. J Biol Chem 282: 25030-25040.
52. Kumar S, Matheny CJ, Hoffman SJ, et al, 2010 An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone 46: 534-542.
53. Fitzpatrick LA, Dabrowski CE, Cicconetti G, et al, 2011 The Effects of Ronacaleret, a Calcium-Sensing Receptor Antagonist, on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Women with Low Bone Mineral Density. J Clin Endocrinol Metab Epub ahead of print: PMID: 21593114.
54. Balan G, Bauman J, Bhattacharya S, et al, 2009 The discovery of novel calcium sensing receptor negative allosteric modulators. Bioorg Med Chem Lett 19: 3328-3332.
55. Yoshida M, Mori A, Kotani E, et al, 2011 Discovery of Novel and Potent Orally Active Calcium-Sensing Receptor Antagonists that Stimulate Pulselike Parathyroid Hormone Secretion: Synthesis and Structure-Activity Relationships of Tetrahydropyrazolopyrimidine Derivatives. J Med Chem 54: 1430-1440.
56. Widler L, Altmann E, Beerli R, et al, 2010 1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: a novel series of potent calcium-sensing receptor antagonists. J Med Chem 53: 2250-2263.
57. Marie PJ, 2010 The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis. Bone 46: 571-576.
58. Sun J, Murphy E, 2010 Calcium-sensing receptor: a sensor and mediator of ischemic preconditioning in the heart. Am J Physiol Heart Circ Physiol 299: H1309-H1317.
59. Hurtel-Lemaire AS, Mentaverri R, Caudrillier A, et al, 2009 The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways. J Biol Chem 284: 575-584.
60. Ma Y, Nyman JS, Tao H, Moss HH, Yang X, Elefteriou F, 2011 β2-Adrenergic Receptor Signaling in Osteoblasts Contributes to the Catabolic Effect of Glucocorticoids on Bone. Endocrinology 152: 1412-1422.
61. Elefteriou F, Ahn JD, Takeda S, et al, 2005 Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434: 514-520.
62. Takeda S, Elefteriou F, Levasseur R, et al, 2002 Leptin regulates bone formation via the sympathetic nervous system. Cell 111: 305-317.
63. Graham S, Hammond-Jones D, Gamie Z, Polyzois I, Tsiridis E, 2008 The effect of beta-blockers on bone metabolism as potential drugs under investigation for osteoporosis and fracture healing. Expert Opin Investig Drugs 17: 1281-1299.
64. Kondo H, Togari A, Continuous treatment with a lowdose beta-agonist reduces bone mass by increasing bone resorption without suppressing bone formation. Calcif Tissue Int 88: 23-32.
65. Bonnet N, Benhamou CL, Malaval L, et al, 2008 Low dose beta-blocker prevents ovariectomy-induced bone loss in rats without affecting heart functions. J Cell Physiol 217: 819-827.
66. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR, 2004 Use of beta-blockers and risk of fractures. JAMA 292: 1326-1332.
67. de Vries F, Souverein PC, Cooper C, Leufkens HG, van Staa TP, 2007 Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands. Calcif Tissue Int 80: 69-75.
68. de Vries F, Pouwels S, Bracke M, et al, 2007 Use of beta-2 agonists and risk of hip/femur fracture: a populationbased case-control study. Pharmacoepidemiol Drug Saf 16: 612-619.
69. Wiens M, Etminan M, Gill SS, Takkouche B, 2006 Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies. J Intern Med 260: 350-362.
70. Bonnet N, Gadois C, McCloskey E, et al, 2007 Protective effect of beta blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture. Bone 40: 1209-1216.
71. Meisinger C, Heier M, Lang O, Doring A, 2007 Betablocker use and risk of fractures in men and women from the general population: the MONICA/KORA Augsburg cohort study. Osteoporos Int 18: 1189-1195.
72. Yang S, Nguyen ND, Center JR, Eisman JA, Nguyen TV, 2011 Association between beta-blocker use and fracture risk: The Dubbo Osteoporosis Epidemiology Study. Bone 48: 451-455.
73. Schmitt CP, Obry J, Feneberg R, et al, 2003 Beta1-adrenergic blockade augments pulsatile PTH secretion in humans. J Am Soc Nephrol 14: 3245-3250.
74. Clevers H, 2006 Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480.
75. Semenov MV, Habas R, Macdonald BT, He X, 2007 SnapShot: Noncanonical Wnt Signaling Pathways. Cell 131: 1378.
76. Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S, 2005 Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and-independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem 280: 41342-41351.
77. Yavropoulou MP, Yovos JG, 2007 The role of the Wnt signaling pathway in osteoblast commitment and differentiation. Hormones (Athens) 6: 279-294.
78. Milat F, Ng KW, 2009 Is Wnt signalling the final common pathway leading to bone formation? Mol Cell Endocrinol 310: 52-62.
79. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R, 1997 beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16: 3797-3804.
80. Mao J, Wang J, Liu B, et al, 2001 Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol Cell 7: 801-809.
81. He X, Saint-Jeannet JP, Wang Y, Nathans J, Dawid I, Varmus H, 1997 A member of the Frizzled protein family mediating axis induction by Wnt-5A. Science 275: 1652-1654.
82. Kawano Y, Kypta R, 2003 Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116: 2627-2634.
83. Topol L, Jiang X, Choi H, Garrett-Beal L, Carolan PJ, Yang Y, 2003 Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J Cell Biol 162: 899-908.
84. Bodine PV, Zhao W, Kharode YP, et al, 2004 The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol 18: 1222-1237.
85. Semenov MV, Tamai K, Brott BK, Kuhl M, Sokol S, He X, 2001 Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr Biol 11: 951-961.
86. Mao B, Wu W, Davidson G, et al, 2002 Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 417: 664-667.
87. Semenov M, Tamai K, He X, 2005 SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 280: 26770-26775.
88. Gong Y, Slee RB, Fukai N, et al, 2001 LDL receptorrelated protein 5 (LRP5) affects bone accrual and eye development. Cell 107: 513-523.
89. Streeten EA, McBride D, Puffenberger E, et al, 2008 Osteoporosis-pseudoglioma syndrome: description of 9 new cases and beneficial response to bisphosphonates. Bone 43: 584-590.
90. Little RD, Carulli JP, Del Mastro RG, et al, 2002 A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70: 11-19.
91. Boyden LM, Mao J, Belsky J, et al, 2002 High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346: 1513-1521.
92. Van Wesenbeeck L, Cleiren E, Gram J, et al, 2003 Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 72: 763-771.
93. Mani A, Radhakrishnan J, Wang H, et al, 2007 LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 315: 1278-1282.
94. Balemans W, Ebeling M, Patel N, et al, 2001 Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10: 537-543.
95. Brunkow ME, Gardner JC, Van Ness J, et al, 2001 Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68: 577-589.
96. Loots GG, Kneissel M, Keller H, et al, 2005 Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 15: 928-935.
97. Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL, 2010 Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 87: 99-107.
98. Li X, Ominsky MS, Warmington KS, et al, 2009 Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24: 578-588.
99. Li X, Warmington KS, Niu QT, et al, 2010 Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 25: 2371-2380.
100. Ominsky MS, Vlasseros F, Jolette J, et al, Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 25: 948-959.
101. Padhi D, Jang G, Stouch B, Fang L, Posvar E, 2011 Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26: 19-26.
102. Lewiecki EM, 2011 Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis. Expert Opin Biol Ther 11: 117-127.
103. Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P, 2010 Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 25: 2412-2418.
104. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD, Jr., 2007 Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109: 2106-2111.
105. Betts AM, Clark TH, Yang J, et al, 2010 The application of target information and preclinical pharmacokinetic/ pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther 333: 2-13.
106. Clement-Lacroix P, Ai M, Morvan F, et al, 2005 Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci U S A 102: 17406-17411.
107. Kulkarni NH, Onyia JE, Zeng Q, et al, 2006 Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res 21: 910-920.
108. Bodine PV, Stauffer B, Ponce-de-Leon H, et al, 2009 A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation. Bone 44: 1063-1068.
109. Bliziotes M, 2011 Update in serotonin and bone. J Clin Endocrinol Metab 95: 4124-4132.
110. Yadav VK, Ducy P, 2010 Lrp5 and bone formation: A serotonin-dependent pathway. Ann N Y Acad Sci 1192: 103-109.
111. Karsenty G, Yadav VK, 2011 Regulation of bone mass by serotonin: molecular biology and therapeutic implications. Annu Rev Med 62: 323-331.
112. Yadav VK, Oury F, Suda N, et al, 2009 A serotonindependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 138: 976-989.
113. Cui Y, Niziolek PJ, Macdonald BT, et al, 2011 Lrp5 functions in bone to regulate bone mass. Nat Med 17: 684-691.
114. Yadav VK, Ryu JH, Suda N, et al, 2008 Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135: 825-837.
115. Yadav VK, Balaji S, Suresh PS, et al, 2010 Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med 16: 308-312.
116. Warden SJ, Robling AG, Sanders MS, Bliziotes MM, Turner CH, 2005 Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 146: 685-693.
117. Westbroek I, Waarsing JH, van Leeuwen JP, et al, 2007 Long-term fluoxetine administration does not result in major changes in bone architecture and strength in growing rats. J Cell Biochem 101: 360-368.
118. Kinjo M, Setoguchi S, Schneeweiss S, Solomon DH, 2005 Bone mineral density in subjects using central nervous system-active medications. Am J Med 118: 1414.
119. Spangler L, Scholes D, Brunner RL, et al, 2008 Depressive symptoms, bone loss, and fractures in postmenopausal women. J Gen Intern Med 23: 567-574.
120. Richards JB, Papaioannou A, Adachi JD, et al, 2007 Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 167: 188-194.
121. Haney EM, Chan BK, Diem SJ, et al, 2007 Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 167: 1246-1251.
122. Diem SJ, Blackwell TL, Stone KL, et al, 2007 Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 167: 1240-1245.
123. Vestergaard P, 2009 Fracture risks of antidepressants. Expert Rev Neurother 9: 137-141.
124. Bolton JM, Metge C, Lix L, Prior H, Sareen J, Leslie WD, 2008 Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol 28: 384-391.
125. Lewis CE, Ewing SK, Taylor BC, et al, 2007 Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res 22: 211-219.
126. Ziere G, Dieleman JP, van der Cammen TJ, Hofman A, Pols HA, Stricker BH, 2008 Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol 28: 411-417.
127. Hubbard R, Farrington P, Smith C, Smeeth L, Tattersfield A, 2003 Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 158: 77-84.
128. Verdel BM, Souverein PC, Egberts TC, van Staa TP, Leufkens HG, de Vries F, Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone 47: 604-609.
129. Modder UI, Achenbach SJ, Amin S, Riggs BL, Melton LJ, 3rd, Khosla S, 2010 Relation of serum serotonin levels to bone density and structural parameters in women. J Bone Miner Res 25: 415-422.
130. Bilezikjian LM, Blount AL, Donaldson CJ, Vale WW, 2006 Pituitary actions of ligands of the TGF-beta family: activins and inhibins. Reproduction 132: 207-215.
131. Zaidi M, Blair HC, Iqbal J, et al, 2009 New insights: elevated follicle-stimulating hormone and bone loss during the menopausal transition. Curr Rheumatol Rep 11: 191-195.
132. Reame NE, Lukacs JL, Olton P, Ansbacher R, Padmanabhan V, 2007 Differential effects of aging on activin A and its binding protein, follistatin, across the menopause transition. Fertil Steril 88: 1003-1005.
133. Eijken M, Swagemakers S, Koedam M, et al, 2007 The activin A-follistatin system: potent regulator of human extracellular matrix mineralization. FASEB J 21: 2949-2960.
134. Oue Y, Kanatani H, Kiyoki M, Eto Y, Ogata E, Matsumoto T, 1994 Effect of local injection of activin A on bone formation in newborn rats. Bone 15: 361-366.
135. Hashimoto M, Shoda A, Inoue S, et al, 1992 Functional regulation of osteoblastic cells by the interaction of activin-A with follistatin. J Biol Chem 267: 4999-5004.
136. Ikenoue T, Jingushi S, Urabe K, Okazaki K, Iwamoto Y, 1999 Inhibitory effects of activin-A on osteoblast differentiation during cultures of fetal rat calvarial cells. J Cell Biochem 75: 206-214.
137. Vale W, Wiater E, Gray P, Harrison C, Bilezikjian L, Choe S, 2004 Activins and inhibins and their signaling. Ann N Y Acad Sci 1038: 142-147.
138. Vallet S, Mukherjee S, Vaghela N, et al, 2010 Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA 107: 5124-5129.
139. Sun L, Peng Y, Sharrow AC, et al, 2006 FSH directly regulates bone mass. Cell 125: 247-260.
140. Prior JC, 2007 FSH and bone--important physiology or not? Trends Mol Med 13: 1-3.
141. Sakai R, Miwa K, Eto Y, 1999 Local administration of activin promotes fracture healing in the rat fibula fracture model. Bone 25: 191-196.
142. Pearsall RS, Canalis E, Cornwall-Brady M, et al, 2008 A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci U S A 105: 7082-7087.
143. Koncarevic A, Cornwall-Brady M, Pullen A, et al, 2010 A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health. Endocrinology 151: 4289-4300.
144. Ogawa Y, Schmidt DK, Nathan RM, et al, 1992 Bovine bone activin enhances bone morphogenetic proteininduced ectopic bone formation. J Biol Chem 267: 14233-14237.
145. Gaddy-Kurten D, Coker JK, Abe E, Jilka RL, Manolagas SC, 2002 Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. Endocrinology 143: 74-83.
146. Fajardo RJ, Manoharan RK, Pearsall RS, et al, 2010 Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis). Bone 46: 64-71.
147. Lotinun S, Pearsall RS, Davies MV, et al, 2010 A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 46: 1082-1088.
148. Ruckle J, Jacobs M, Kramer W, et al, 2009 Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 24: 744-752.
149. Canalis E, 2009 Growth factor control of bone mass. J Cell Biochem 108: 769-777.
150. Canalis E, Economides AN, Gazzerro E, 2003 Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24: 218-235.
151. Daluiski A, Engstrand T, Bahamonde ME, et al, 2001 Bone morphogenetic protein-3 is a negative regulator of bone density. Nat Genet 27: 84-88.
152. Payne C, King J, Hay D, 2011 The role of activin/nodal and Wnt signaling in endoderm formation. Vitam Horm 85: 207-216.
153. Kamiya N, Ye L, Kobayashi T, et al, 2008 BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development 135: 3801-3811.
154. Axelrad TW, Einhorn TA, 2009 Bone morphogenetic proteins in orthopaedic surgery. Cytokine Growth Factor Rev 20: 481-488.
155. El-Amin SF, Hogan MV, Allen AA, Hinds J, Laurencin CT, 2010 The indications and use of bone morphogenetic proteins in foot, ankle, and tibia surgery. Foot Ankle Clin 15: 543-551.
156. Kanakaris NK, Petsatodis G, Tagil M, Giannoudis PV, 2009 Is there a role for bone morphogenetic proteins in osteoporotic fractures? Injury 40 Suppl 3: S21-S26.
157. Matsumoto A, Yamaji K, Kawanami M, Kato H, 2001 Effect of aging on bone formation induced by recombinant human bone morphogenetic protein-2 combined with fibrous collagen membranes at subperiosteal sites. J Periodontal Res 36: 175-182.
158. Turgeman G, Zilberman Y, Zhou S, et al, 2002 Systemically administered rhBMP-2 promotes MSC activity and reverses bone and cartilage loss in osteopenic mice. J Cell Biochem 86: 461-474.
159. Simic P, Culej JB, Orlic I, et al, 2006 Systemically administered bone morphogenetic protein-6 restores bone in aged ovariectomized rats by increasing bone formation and suppressing bone resorption. J Biol Chem 281: 25509-25521.
160. Phillips FM, Voronov LI, Gaitanis IN, Carandang G, Havey RM, Patwardhan AG, 2006 Biomechanics of posterior dynamic stabilizing device (DIAM) after facetectomy and discectomy. Spine J 6: 714-722.
161. Rose T, Peng H, Usas A, Josten C, Fu FH, Huard J, 2005 [Ex-vivo gene therapy with BMP-4 for critically sized defects and enhancement of fracture healing in an osteoporotic animal model]. Unfallchirurg 108: 25-34.
162. Tang DZ, Hou W, Zhou Q, et al, 2010 Osthole stimulates osteoblast differentiation and bone formation by activation of beta-catenin-BMP signaling. J Bone Miner Res 25: 1234-1245.
163. Lee SU, Park SJ, Kwak HB, Oh J, Min YK, Kim SH, 2008 Anabolic activity of ursolic acid in bone: Stimulating osteoblast differentiation in vitro and inducing new bone formation in vivo. Pharmacol Res 58: 290-296.
164. Chang JK, Hsu YL, Teng IC, Kuo PL, 2006 Piceatannol stimulates osteoblast differentiation that may be mediated by increased bone morphogenetic protein-2 production. Eur J Pharmacol 551: 1-9.
165. Wu JB, Fong YC, Tsai HY, Chen YF, Tsuzuki M, Tang CH, 2008 Naringin-induced bone morphogenetic protein-2 expression via PI3K, Akt, c-Fos/c-Jun and AP-1 pathway in osteoblasts. Eur J Pharmacol 588: 333-341.
166. Takayama K, Suzuki A, Manaka T, et al, 2009 RNA interference for noggin enhances the biological activity of bone morphogenetic proteins in vivo and in vitro. J Bone Miner Metab 27: 402-411.
167. Gazzerro E, Smerdel-Ramoya A, Zanotti S, et al, 2007 Conditional deletion of gremlin causes a transient increase in bone formation and bone mass. J Biol Chem 282: 31549-31557.
168. Garrison KR, Shemilt I, Donell S, et al, 2010 Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev: CD006950.
169. Bessa PC, Balmayor ER, Hartinger J, et al, 2010 Silk fibroin microparticles as carriers for delivery of human recombinant bone morphogenetic protein-2: in vitro and in vivo bioactivity. Tissue Eng Part C Methods 16: 937-945.
170. Ghiron LJ, Thompson JL, Holloway L, et al, 1995 Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women. J Bone Miner Res 10: 1844-1852.
171. Rudman D, Feller AG, Nagraj HS, et al, 1990 Effects of human growth hormone in men over 60 years old. N Engl J Med 323: 1-6.
172. Canalis EM, Hintz RL, Dietrich JW, Maina DM, Raisz LG, 1977 Effect of somatomedin and growth hormone on bone collagen synthesis in vitro. Metabolism 26: 1079-1087.
173. Canalis E, 1980 Effect of insulinlike growth factor I on DNA and protein synthesis in cultured rat calvaria. J Clin Invest 66: 709-719.
174. Isgaard J, Nilsson A, Lindahl A, Jansson JO, Isaksson OG, 1986 Effects of local administration of GH and IGF-1 on longitudinal bone growth in rats. Am J Physiol 250: E367-E372.
175. Spencer EM, Liu CC, Si EC, Howard GA, 1991 In vivo actions of insulin-like growth factor-I (IGF-I) on bone formation and resorption in rats. Bone 12: 21-6.
176. Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM, 1994 Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 78: 669-674.
177. Johansson AG, Burman P, Westermark K, Ljunghall S, 1992 The bone mineral density in acquired growth hormone deficiency correlates with circulating levels of insulin-like growth factor I. J Intern Med 232: 447-452.
178. Wuster C, Abs R, Bengtsson BA, et al, 2001 The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 16: 398-405.
179. Murray RD, Columb B, Adams JE, Shalet SM, 2004 Low bone mass is an infrequent feature of the adult growth hormone deficiency syndrome in middle-age adults and the elderly. J Clin Endocrinol Metab 89: 1124-1130.
180. Colao A, Di Somma C, Cuocolo A, et al, 2004 The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: an observational, case-control study. J Clin Endocrinol Metab 89: 5998-6004.
181. Langlois JA, Rosen CJ, Visser M, et al, 1998 Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham Heart Study. J Clin Endocrinol Metab 83: 4257-4262.
182. Bex M, Abs R, Maiter D, Beckers A, Lamberigts G, Bouillon R, 2002 The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. J Bone Miner Res 17: 1081-1094.
183. Cuneo RC, Judd S, Wallace JD, et al, 1998 The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults. J Clin Endocrinol Metab 83: 107-116.
184. Hoffman AR, Kuntze JE, Baptista J, et al, 2004 Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebocontrolled trial. J Clin Endocrinol Metab 89: 2048-2056.
185. Baum HB, Biller BM, Finkelstein JS, et al, 1996 Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 125: 883-890.
186. Snyder PJ, Biller BM, Zagar A, et al, 2007 Effect of growth hormone replacement on BMD in adult-onset growth hormone deficiency. J Bone Miner Res 22: 762-770.
187. Holloway L, Butterfield G, Hintz RL, Gesundheit N, Marcus R, 1994 Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. J Clin Endocrinol Metab 79: 470-479.
188. Holloway L, Kohlmeier L, Kent K, Marcus R, 1997 Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women. J Clin Endocrinol Metab 82: 1111-1117.
189. Aloia JF, Zanzi I, Ellis K, et al, 1976 Effects of growth hormone in osteoporosis. J Clin Endocrinol Metab 43: 992-999.
190. Kruse HP, Kuhlencordt F, 1975 On an attempt to treat primary and secondary osteoporosis with human growth hormone. Horm Metab Res 7: 488-491.
191. Aloia JF, Vaswani A, Kapoor A, Yeh JK, Cohn SH, 1985 Treatment of osteoporosis with calcitonin, with and without growth hormone. Metabolism 34: 124-129.
192. Friedlander AL, Butterfield GE, Moynihan S, et al, 2001 One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal women. J Clin Endocrinol Metab 86: 1496-1503.
193. Canalis E, Giustina A, Bilezikian JP, 2007 Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357: 905-916.